---
title: "GLAXO: Strong Q1 FY27 growth driven by innovation, market leadership, and improved profitability"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294681139.md"
description: "Revenue and profit grew strongly in Q1 FY27, led by portfolio transformation and innovation. Key brands and vaccines maintained market leadership, with new launches in oncology and respiratory segments driving growth. EBITDA and PAT margins improved year-over-year.Original document: GlaxoSmithKline Pharmaceuticals Limited [GLAXO] Slides Release — Aug. 3 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-03T10:48:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294681139.md)
  - [en](https://longbridge.com/en/news/294681139.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294681139.md)
generator: "portal-rs"
---

# GLAXO: Strong Q1 FY27 growth driven by innovation, market leadership, and improved profitability

Revenue and profit grew strongly in Q1 FY27, led by portfolio transformation and innovation. Key brands and vaccines maintained market leadership, with new launches in oncology and respiratory segments driving growth. EBITDA and PAT margins improved year-over-year.

Original document: GlaxoSmithKline Pharmaceuticals Limited \[GLAXO\] Slides Release — Aug. 3 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)

## Related News & Research

- [REG - GSK PLC - Director/PDMR Shareholding](https://longbridge.com/en/news/296244146.md)
- [GSK: Strong core growth in Q2 2026, robust R&D acceleration, and major restructuring underway](https://longbridge.com/en/news/294062275.md)
- [Walmart store workers have a new responsibility: correcting AI errors](https://longbridge.com/en/news/296213777.md)
- [GSK now expects 20+ phase III trial starts in 2026, up from 10](https://longbridge.com/en/news/294056670.md)
- [AMLX: Avexitide achieved a 55% reduction in severe hypoglycemic events in PBH, with strong safety data](https://longbridge.com/en/news/296234006.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**